Morgan Stanley’s CinCor Pharma, Inc. Common Stock CINC Stock Holding History

Morgan Stanley’s Portfolio CINC Stock Details CINC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-27,204	Closed	-$334K	–	7944
2022 Q4	$334K	Sell	27,204 -49,546	-65%	-$1.18M	﹤0.01%	5439
2022 Q3	$2.52M	Buy	76,750 +53,667	+232%	+$1.52M	﹤0.01%	4270
2022 Q2	$434K	Buy	23,083 +20,040	+659%	+$384K	﹤0.01%	5490
2022 Q1	$53K	Buy	+3,043	New	+$62.4K	﹤0.01%	6682

Morgan Stanley's CINC Position: Q1 2023 in Review

Morgan Stanley sold out of CinCor Pharma, Inc. Common Stock (CINC) in Q1 2023, closing a stake of 27,204 shares — an estimated $334K sold.

Morgan Stanley first reported a position in CINC in Q1 2022 and held it in 4 quarters. The position peaked at $2.52M in Q3 2022. 0 funds tracked by Wall St. Rank hold CINC as of Q1 2023.

Morgan Stanley reported no remaining CinCor Pharma, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Morgan Stanley sold 27,204 CinCor Pharma, Inc. Common Stock shares in Q1 2023, an estimated $334K.
Morgan Stanley first reported a position in CinCor Pharma, Inc. Common Stock in Q1 2022 and held it in 4 quarters.
Morgan Stanley's CinCor Pharma, Inc. Common Stock position peaked at $2.52M in Q3 2022.
0 funds tracked by Wall St. Rank held CinCor Pharma, Inc. Common Stock as of Q1 2023.

Based on Morgan Stanley's 13F filing for Q1 2023, filed 15 May 2023.